Jul 3, 2025 4:30 pm EDT Opus Genetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 26, 2025 6:55 am EDT Opus Genetics Announces VEGA-3 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
Jun 23, 2025 8:00 am EDT Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Support Preclinical Development of OPGx-MERTK Program
Jun 2, 2025 8:00 am EDT Opus Genetics Announces LYNX-2 Phase 3 Trial Met its Primary Endpoint for Phentolamine Ophthalmic Solution 0.75% in Keratorefractive Patients with Visual Disturbances Under Mesopic, Low-Contrast Conditions
May 15, 2025 8:00 am EDT Opus Genetics Announces Financial Results for First Quarter 2025 and Provides Corporate Update
May 12, 2025 8:00 am EDT Opus Genetics Announces Presentations on Inherited Retinal Disease Programs at Medical Conferences in May
May 6, 2025 8:00 am EDT Opus Genetics Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for OPGx-LCA5 Gene Therapy Candidate
May 5, 2025 8:00 am EDT Opus Genetics Announces Presentation of OPGX-LCA5 Gene Therapy Data at ARVO; 12 Month Phase 1/2 Results Support Potential to Restore to Meaningful Vision
Apr 8, 2025 8:00 am EDT Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases
Apr 7, 2025 8:00 am EDT Opus Genetics Files Definitive Proxy Statement and Sends Letter to Stockholders Highlighting the Company’s Transformation and Progress